- Home
- RSVR vs CVAC Comparison
RSVR vs CVAC Comparison
Compare RSVR & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSVR
- CVAC
- Stock Information
- Founded
- RSVR 2007
- CVAC 2000
- Country
- RSVR United States
- CVAC Germany
- Employees
- RSVR N/A
- CVAC N/A
- Industry
- RSVR Movies/Entertainment
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- RSVR Consumer Discretionary
- CVAC Health Care
- Exchange
- RSVR Nasdaq
- CVAC Nasdaq
- Market Cap
- RSVR 562.3M
- CVAC 637.1M
- IPO Year
- RSVR N/A
- CVAC 2020
- Fundamental
- Price
- RSVR $9.28
- CVAC $2.95
- Analyst Decision
- RSVR Strong Buy
- CVAC Hold
- Analyst Count
- RSVR 1
- CVAC 3
- Target Price
- RSVR $12.50
- CVAC $10.00
- AVG Volume (30 Days)
- RSVR 36.3K
- CVAC 523.1K
- Earning Date
- RSVR 02-05-2025
- CVAC 11-12-2024
- Dividend Yield
- RSVR N/A
- CVAC N/A
- EPS Growth
- RSVR N/A
- CVAC N/A
- EPS
- RSVR N/A
- CVAC N/A
- Revenue
- RSVR $149,606,040.00
- CVAC $70,565,734.00
- Revenue This Year
- RSVR $7.18
- CVAC $738.59
- Revenue Next Year
- RSVR $7.33
- CVAC N/A
- P/E Ratio
- RSVR N/A
- CVAC N/A
- Revenue Growth
- RSVR 10.84
- CVAC 75.11
- 52 Week Low
- RSVR $5.95
- CVAC $2.22
- 52 Week High
- RSVR $9.83
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- RSVR 54.05
- CVAC 49.55
- Support Level
- RSVR $8.99
- CVAC $3.17
- Resistance Level
- RSVR $9.59
- CVAC $3.56
- Average True Range (ATR)
- RSVR 0.29
- CVAC 0.18
- MACD
- RSVR -0.05
- CVAC 0.01
- Stochastic Oscillator
- RSVR 34.91
- CVAC 24.69
About RSVR Reservoir Media Inc.
Reservoir Media Inc is an independent music company. The company's segment includes Music Publishing; Recorded Music and others. It generates the maximum of its revenue from the Music Publishing segment.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.